About
Dan Curto
Founder of Curto Pharma Law. Experienced legal and compliance counsel to pharmaceutical and biotechnology companies, with fourteen years at McDermott Will & Emery and a decade in senior in-house roles.

Background
14 years at McDermott Will & Emery – 10 years in-house
I founded Curto Pharma Law in 2021 after more than two decades advising life sciences companies, first as outside counsel and then as a senior in-house lawyer. I bring practical value and experienced judgment to all stages of drug development and commercialization.
At McDermott Will & Emery, where I spent 14 years and became a partner, I guided life sciences companies through government investigations, litigation and compliance remediation. In-house at Biogen, Sanofi and BeiGene, I led global investigations, litigation and commercial legal support, working alongside the commercial, medical and clinical teams whose decisions legal advice has to fit.
Clients work with me directly and get experienced judgment at a reasonable cost, without layers of associates or large-firm overhead. My practice covers internal investigations, compliance assessments, clinical trial setup and privacy, and contracting (collaborations, supply agreements, MTAs, SRAs and clinical trial agreements), including sensitive and cross-border matters.
Career
Where the experience comes from
Representative experience
Selected work
Client names withheld. Prior results do not guarantee a similar outcome.
Internal investigations
Oversaw hundreds of internal investigations involving commercial, medical, research misconduct, clinical trial quality and manufacturing issues.
Government investigations
Managed the defense of federal and state investigations involving anti-kickback issues related to health care professional (HCP) payments, patient support programs, drug pricing, marketing the spread, off-label promotion and GMP manufacturing.
Compliance programs and remediation
Created, revamped or audited investigation protocols and standard operating procedures for numerous life sciences companies, and worked with internal audit on privileged audits of HCP engagement, patient assistance and research grant functions.
Clinical trials and research agreements
Served as legal counsel on numerous Phase 3 clinical trials, handling contracting, privacy, GCP and pharmacovigilance issues.
Commercial compliance and third-party risk
Investigated potential FCPA matters across Asia, Europe, the Middle East and Latin America, developed distributor compliance controls, and revamped HCP engagement procedures to reflect updated OIG guidance on speaker programs.
Have a matter to discuss?
Most engagements begin with a short call.